A Phase IIa Observer-blind, Randomized, Controlled, Age-de-escalation, Single Center Interventional Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GVGH iNTS Vaccine Against S. Typhimurium and S. Enteritidis, in Adults, Children and Infants, Including Dose-finding in Infants, in Africa

The purpose of this study is to evaluate the safety, reactogenicity, and immune response of the GlaxoSmithKline (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-generalized modules for membrane antigens (iNTS-GMMA) candidate vaccine against S. Typhimurium and S. Enteritidis with an age de-escalation and dose escalation approach in African population, starting with adults (18-50 years of age), then on children (24-59 months of age) and finally to infants (9 months and 6 weeks of age). Infants are the target for primary vaccination from 6 weeks of age.

开始日期2024-01-15

申办/合作机构

GSK Plc

[+2]

TCTR20231108008 / Not yet recruiting临床4期

A Phase IV, Non-Inferiority, Double Blind, Randomized Controlled Clinical Trial comparing Safety and Immunogenicity of SII-Measles-Mumps-Rubella vaccine with Priorix (GSK) in healthy infants

开始日期2024-01-01

申办/合作机构-

NCT05630846 / Recruiting临床2期

A Phase II, Single-blind, Randomized, Controlled Study to Evaluate the Immunogenicity and Safety of a Measles, Mumps, Rubella, Varicella Vaccine Compared With ProQuad, Administered in Healthy Children 4-6 Years of Age

The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.

开始日期2022-12-14

申办/合作机构

GSK Plc

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的临床结果

登录后查看更多信息

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的转化医学

登录后查看更多信息

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的专利（医药）

登录后查看更多信息

1,987

项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的文献（医药）

2024-12-31·Human vaccines & immunotherapeutics

A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine.

Review

作者: Nitin Shah ; Apurba Ghosh ; Kishore Kumar ; Trayambak Dutta ; Manish Mahajan

Measles, mumps, and rubella (MMR) are highly infectious viral diseases affecting young children and have high secondary attack rates. Present MMR vaccines show consistent seroconversion rates for anti-measles and anti-rubella antibodies with variable responses for anti-mumps antibodies. Most common strains for MMR vaccines, currently available in India, are the Edmonston-Zagreb measles strain, Leningrad Zagreb (L-Z) mumps strain, and the RA 27/3 rubella strain. L-Z strain of mumps virus has been found to be associated with aseptic meningitis by different studies from different parts of the world including India. Recently, a novel freeze-dried MMR vaccine developed by Zydus Lifesciences (Zyvac MMR) contains Edmonston Zagreb measles strain, Hoshino mumps strain, and RA 27/3 rubella strain. The Hoshino strain is WHO approved and was found to induce interferon gamma production. This review article aims to provide a comprehensive appraisal of the data available on the safety and immunogenicity of the novel MMR vaccine.

2024-03-01·Vaccine: X

Overview of childhood vaccination coverage in Brazil and the impact of the COVID-19 pandemic: Is our children's health at risk? A review of pre-COVID-19 periods and during the COVID-19 pandemic.

Article

作者: Jéssica Paula Martins ; Giulia Almeida Alatzatianos ; Tais Mendes Camargo ; Fernando Augusto Lima Marson

Introduction:

The coronavirus disease (COVID)-19 has had a great impact on several aspects related to the population's health, including the vaccination adherence rate. This study describes how childhood vaccination coverage (CVC) in Brazil was affected by the pandemic in the period from 2020 to 2022 and explores the relationship between this data and the Human Development Index (HDI), and the number of votes received in the government with a right-wing political ideology.

Methods:

An ecological analysis of CVC was carried out including 12 vaccines. The HDI was evaluated considering the HDI-General, HDI-Income, HDI-Longevity, and HDI-Education. The percentage of valid votes received by the former president (right-wing political ideology) was also obtained. Spearman correlation tests were applied to compare markers.

Results:

During the period analyzed, it was observed a linear growth trend in CVC between 2015 and 2018 regarding all vaccines. However, from 2018 onwards, after the presidential elections in Brazil, the CVC reduced significantly, showing an even more pronounced decrease with the start of the COVID-19 pandemic. This reduction in CVC observed for some vaccines was related to the higher percentage of votes for the government with a right-wing political ideology, especially in relation to the BCG (bacillus Calmette and Guerin) and pentavalent (protecting against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b bacteria) vaccines. In addition, when analyzing the HDI, it was observed that the lowest values of this indicator were associated with a more expressive reduction in CVC, mainly related to yellow fever, pentavalent, 10-valent pneumococcal conjugate, Human rotavirus, and triple viral (protecting against measles, mumps, and rubella - MMR) vaccines.

Conclusion:

Although Brazil has a successful and exemplary record in combating several diseases, mainly due to the high rate of CVC, the continuous reduction in this coverage must be thoroughly evaluated by health managers.

2024-02-03·International journal of medical microbiology : IJMM

Measles vaccination - An underestimated prevention measure: Analyzing a fatal case in Hildesheim, Germany.

Article

作者: Katharina Hueppe ; Jan Ortman ; Hannah Gauselmann ; Sabine Santibanez ; Annette Mankertz

Measles and rubella are targeted for elimination in the WHO region Europe. To reach the elimination goal, vaccination coverage of 95% must be achieved and sustained, the genotype information has to be provided for 80% of all outbreaks and transmission chains of a certain variant must not be detected for >12 months. The latter information is collected at Germany's National Reference Center Measles, Mumps, Rubella (NRC MMR). We describe here an outbreak of measles occurring in Hildesheim. The outbreak comprised 43 cases and lasted 14 weeks. Surprisingly, a high number of vaccination failures was observed since 11 cases had received two doses of the MMR vaccine and 4 additional cases were vaccinated once. A 33-year-old woman passed away during the outbreak. She was the mother of 5 children between 4 and 16 years of age. Two schoolchildren contracted measles and passed it on to the rest of the family. Due to delivery bottlenecks, the vaccination of the mother was delayed. She developed measles-like symptoms 3 days after vaccination and was found dead on the morning of day 8 after vaccination. A post-mortem examination was done to identify the cause of death. Moreover, molecular characterization of the virus was performed to analyze whether she was infected by the wildtype virus circulating at that time in Hildesheim or whether the vaccine may have been a concomitant and aggravating feature of her death. The result showed that the samples taken from her at the time of death and during necropsy contained the wildtype measles virus variant corresponding to MVs/Gir Somnath.IND/42.16 (WHO Seq-ID D8-4683) that fueled the Hildesheim outbreak and circulated in Germany from March 2018 to March 2020. The vaccine virus was not detected. Moreover, two aspects uncovered by the post-mortem examination were remarkable; the woman died from giant cell pneumonia, which is a complication seen in immune-suppressed individuals and she was actively using cannabis. THC is known to influence the immune system, but literature reports describing the effects are limited.

项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的新闻（医药）

2024-04-05

·Pharmaceutical Technology

England’s MMR vaccinations up 23% following NHS initiative

Vaccinations were up four fold in those aged five to 25 years old. Image credit: Shutterstock/didesign021. England’s NHS is calling its recent campaign to boost vaccination rates a success amidst a surge in measles, mumps , and rubella (MMR) cases. Latest data released by the health service shows that there were 23% more vaccinations in the first quarter of 2024 compared to the same time last year. A total of 360,964 jabs were delivered between January and March this year, compared to 293,847 in 2023. The biggest jump was seen in those aged five to 25 years old, with vaccinations up four-fold in that group between 2024 and 2023. In January, the UK Health Security Agency (UKHSA) declared a national incident following a surge in measles outbreaks across Britain. The highly contagious measles virus can cause serious illness and, in some cases, even death, in children and adults. It is also dangerous if caught during pregnancy, potentially resulting in stillbirth, miscarriage, and low birth weight. In the same month, the NHS started contacting millions of patients and carers in England to book their children in for a catch-up vaccine with a GP. The campaign also targeted those in the 11 to 25 year-age group in areas with low vaccine uptake rates such as London and the West Midlands. See Also: Touchlight joins forces with University of Liverpool for NSCLC vaccine Zoetis gets grant for recombinant viral vectors for multivalent pathogen protection in vaccines At the time, the NHS said its figures indicated that more than 3.4 million children under 16 years of age were unprotected against the three infectious diseases. There have been 934 confirmed cases of measles in England since the beginning of October last year, according to data from the UKSHA. The West Midlands accounted for around half of the cases seen since January. UKSHA head of immunisation Dr Mary Ramsay said: “The big increase in people, especially children, getting their MMR vaccine following our recent marketing campaign on missed immunisations is fantastic to see.” The NHS uses MSD’s M-M-RVaxPro and GSK ’s Priorix for MMR vaccines. The shots were approved for use in the UK in 1997 and 2006, respectively. They are recommended for all babies and young children, with adults able to receive one if unvaccinated. Two doses of the vaccines are required, resulting in lifelong protection with high efficacy against the three viruses which are easily spread between unvaccinated people. The World Health Organization (WHO) has said 95% vaccine coverage would eliminate measles in a population completely. The US has also seen a surge in measles cases , with the Centers for Disease Control and Prevention (CDC) reporting 97 cases in 2024 so far. Over half of the patients diagnosed with the virus were hospitalised. The CDC issued a health alert urging travellers, especially children, to get vaccinated. A statement from the American Medical Association echoed the call for vaccinations. The US also uses MSD’s M-M-R II and GSK’s Priorix.

疫苗上市批准

2024-03-12

·生物制品圈

2024年美国免疫实践咨询委员会≥19岁成人疫苗推荐免疫程序

2023年10月，美国免疫实践咨询委员会（ACIP）批准了2024年美国≥19岁成人疫苗推荐免疫程序。该程序每年发布一次，以整合和总结ACIP关于成人疫苗接种建议的更新，并协助医疗保健提供者实施当前的ACIP建议。ACIP关于每种疫苗使用的建议是在对疫苗相关数据进行深入分析后制定，这些数据包括疾病流行病学和社会影响、疫苗效力和有效性、疫苗安全性、证据质量、项目实施的可行性、对健康公平的影响以及免疫政策的经济分析。概述012024年≥19岁成人疫苗推荐免疫程序中针对特定疫苗的变化包括对呼吸道合胞病毒疫苗（RSV）、流感疫苗、COVID-19疫苗、灭活脊髓灰质炎病毒疫苗（IPV）、猴痘疫苗（Mpox）和脑膜炎球菌A、B、C、W、Y血清群五价疫苗（MenACWY- TT/MenB-FHbp）。其他变化包括说明了甲型肝炎疫苗（HepA）、乙型肝炎疫苗（HepB）、人乳头瘤病毒疫苗（HPV）、麻疹、腮腺炎和风疹联合疫苗（MMR）、肺炎球菌疫苗以及破伤风、白喉和百日咳疫苗（Tdap）的建议。01表1.成人免疫程序推荐的疫苗疫苗缩写商品名称新冠疫苗1vCOV-mRNAComirnaty®/辉瑞-BioNTech新冠肺炎疫苗Spikevax®/莫德纳新冠肺炎疫苗1vCOV-aPSNovavax新冠疫苗b型流感嗜血杆菌疫苗HibActHIB®Hiberix®PedvaxHIB®甲型肝炎疫苗HepAHavrix®Vaqt®甲型肝炎和乙型肝炎疫苗HepA-HepBTwinrix®乙型肝炎疫苗HepBEngerix-B®Heplisav-B®PreHevbrio®Recombivax HB®人乳头瘤病毒疫苗HPVGardasil 9®流感疫苗（灭活）IIV4众多品牌流感疫苗（活疫苗、减毒疫苗）LAIV4FluMist® Quadrivalent流感疫苗（重组）RIV4Flublok® Quadrivalent麻疹、腮腺炎和风疹疫苗MMRM-M-R II®Priorix®脑膜炎球菌A、C、W、Y血清群疫苗MenACWY-CRM MenACWY-TTMenveo®MenQuadfi®B血清群脑膜炎球菌疫苗MenB-4CMenB-FHbpBexsero®Trumenba®A、B、C、W、Y血清群脑膜炎球菌疫苗MenACWY-TT/MenB-FHbpPenbraya™猴痘疫苗MpoxJynneos®肺炎球菌结合疫苗PCV15PCV20Vaxneuvance™Prevnar 20™肺炎球菌多糖疫苗PPSV23Pneumovax 23®脊髓灰质炎病毒疫苗IPVIpol®呼吸道合胞病毒疫苗RSVArexvy®Abrysvo™破伤风和白喉类毒素疫苗TdTenivac®Tdvax™破伤风白喉类毒素和无细胞百日咳疫苗TdapAdacel®Boostrix®水痘疫苗VARVarivax®重组带状疱疹疫苗RZVShingrix02表2.2024年美国按年龄组分列的推荐成人免疫接种时间表03 表3.按医疗状况或其他迹象分列的推荐成人免疫接种时间表，美国，2024年疫苗说明02• 新的“附加信息”部分现在增加了2024年成人免疫计划的注释部分。• COVID-19：现在建议所有成年人至少接种1剂更新的（2023-2024年组分）COVID-19疫苗。所需的剂次数和剂次间隔可能因患者既往疫苗接种史、免疫功能低下状态和使用的疫苗产品而异。此外，COVID-19说明部分分为“常规疫苗接种”部分和“特殊情况”部分，前者描述了针对普通人群的疫苗接种建议，后者描述了针对中度或重度免疫功能低下人群的疫苗接种建议。• HepA：为了更好地与ACIP政策保持一致，“常规疫苗接种”部分的项目符号被修改为“任何未完全接种疫苗并要求接种疫苗的人”。• HepB：在“常规疫苗接种”部分，在描述针对≥60岁人群的基于风险的疫苗接种建议的项目符号中添加了额外的背景和细节。此外，在“常规疫苗接种”部分的末尾增加了一个注释，描述了对≥60岁糖尿病患者的共同临床决策建议。• HPV：在“常规疫苗接种”部分，删除了关于未按免疫程序完成接种的指南。当使用推荐的接种间隔完成全程HPV疫苗接种后，不建议额外剂次。• 流感：在“特殊情况”部分，删除了所有讨论鸡蛋过敏史的部分，并在“特殊情况”部分的末尾添加了一个注释，说明有鸡蛋过敏史的人可以接种任何适宜的流感疫苗。最后，删除了描述吉兰-巴雷综合征的部分。• MMR：对“常规疫苗接种”部分进行了细微更改，以提高语言清晰度。• 脑膜炎球菌：添加了资源链接，以帮助医疗保健提供者共享MenB疫苗接种的临床决策建议。有关使用新许可的五价脑膜炎球菌疫苗（Penbraya）的信息在脑膜炎球菌注释部分的末尾提供。• 猴痘：猴痘疫苗接种是成人疫苗推荐免疫程序注释部分的新内容。列出了需要常规接种Jynneos疫苗的危险因素。有关在医疗保健提供者和孕妇中使用Jynneos的要点在Mpox注释部分的末尾提供。• 肺炎球菌：在“常规疫苗接种”和“特殊情况”部分进行了细微编辑，以明确肺炎球菌疫苗的指导和最低间隔。• 脊髓灰质炎病毒：在“常规疫苗接种”部分添加了其他背景信息。本节现在呼吁未接种疫苗或未完全接种疫苗的成年人完成3剂IPV基础免疫。增加了一份声明，指出大多数在美国出生和长大的成年人可以假设他们小时候接种了脊髓灰质炎疫苗。“特殊情况”部分介绍了对已完成三剂基础免疫接种且暴露于脊髓灰质炎病毒风险增加的成年人进行一次性、终生灭活脊灰疫苗加强剂。• 呼吸道合胞病毒：今年增加了一个新的呼吸道合胞病毒注释部分。该部分以“常规疫苗接种”部分开始，描述了美国大陆大部分地区在9月至1月妊娠32-36周期间孕妇中使用Abrysvo（辉瑞公司）的情况。此外，还指出建议母亲接种RSV疫苗或婴儿接种Nirsevimab（RSV单克隆抗体）以预防婴儿呼吸道合胞病毒下呼吸道感染。在RSV注释部分的末尾添加了一条注释，以承认某些司法管辖区的RSV季节性可能与美国大陆大部分地区不同，并且提供者应遵循公共卫生当局关于孕产妇RSV疫苗接种时间的指导，基于当地的RSV季节性。 “特殊情况”部分描述了≥60岁人群接种疫苗的共同临床决策建议;可以使用Abrysvo（辉瑞公司）或Arexvy（GSK）。此外，还添加了一个资源链接，以帮助医疗保健提供者共享RSV疫苗接种的临床决策建议。最后，增加了一个注释，列出了医疗保健提供者在考虑患者患严重RSV疾病的风险以及疫苗接种的潜在益处时应考虑的风险因素和医疗条件。• Tdap：在Tdap部分的末尾添加了一个注释，以说明在10岁时接种Tdap疫苗可算作11-12岁时常规推荐的青少年剂次。参考文献：Murthy N, Wodi AP, McNally VV, Daley MF, Cineas S. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2024. MMWR Morb Mortal Wkly Rep 2024;73:11–15. DOI：http://dx.doi.org/10.15585/mmwr.mm7301a3识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

疫苗临床研究

2024-02-08

·PRNewswire

Global Market Pipeline for Vaccine Technologies 2024-2028

DUBLIN, Feb. 8, 2024 /PRNewswire/ -- The "Global Markets for Vaccine Technologies" report has been added to ResearchAndMarkets.com's offering. Advancements will occur in regard to the development of novel vaccines towards emerging infectious diseases, cancers and allergies. Continuous improvements in vaccine design, delivery technologies and manufacturing will also boost market growth. The global vaccine technologies market is segmented in this report by technology, disease, age, and region. This report explains critical trends in the vaccine industry. It discusses the market determinants, which act as motivating or restraining factors and provides insights to stakeholders and potential entrants. This report includes only human vaccines; animal vaccines have not been considered in this report. This study looks at research and development (R&D) spending, increasing competition and new technologies, which are giving direction to the market. These advancements, new product launches and changing lifestyles are influencing future market growth. Company mergers, acquisition strategies and collaborations are also covered in this report. Additionally, this study discusses the strengths and weaknesses of each strategy type, considering new technologies, growing competition and changing customer needs. The market has been analyzed based on the application of current vaccines. Categories considered in this report include pneumococcal vaccines; diphtheria, tetanus vaccines; HPV vaccines; MMR vaccines; and other vaccines including rotavirus vaccines, influenza vaccines, hepatitis B vaccines, chickenpox vaccines, polio vaccines, BCG, and yellow fever vaccines. This study details market growth among vaccine manufacturers and end users. Genomic research centers, academic institutions, government and private laboratories, various hospital settings, and pharmaceutical, diagnostic and biotechnology companies and physicians will find this study to be of interest. This report provides useful information to all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this study useful. The Report Includes 34 data tables and 63 additional tables An up-to-date overview of the global markets for vaccine technologies Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028 Estimate of the market size and revenue forecast for the global market, and a corresponding market share analysis based on technology, disease indication, age group and region Facts and figures pertaining to the market drivers, opportunities and challenges, emerging technologies, global R&D spending, and the regulatory landscape Assessment of present and future strategies in the innovation-driven vaccine technologies market, and a look at the vaccines for humans and their immunization schedule Discussion of the importance of ESG in the market for vaccine technologies, including consumer attitudes, the impact of ESG factors on company performance, and ESG practices of leading companies Review of patents and patent applications Overview of the major vendors, along with an analysis of the industry structure, including company market shares, recent M&A activity, and venture funding Analysis of the competitive landscape based on recent developments and segmental revenues Profiles of the leading companies Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market and Technology Background Immune System and Vaccines Components of the Immune System Cells of the Immune System Immune Response Major Histocompatibility Complex (MHC) Immunization and Vaccines Disorders of the Immune System Impact of Lifestyle on the Immune System How Vaccines Work Principles of Immunization Types of Immunity Advantages of Vaccination History of Vaccines Vaccines and Immunization, Overview Types of Vaccines Attenuated (Live) Vaccines Inactivated (Killed) Vaccines Toxoid Vaccines Subunit Vaccines Conjugate Vaccines Recombinant Vector Vaccines DNA Vaccines RNA Vaccines Immunization Advantages of Immunization Adjuvants and Excipients Pathogen Components Particulate Adjuvants Infectious Diseases Preventable by Vaccine Human Diseases Viral Diseases Bacterial Diseases Regulatory Aspects World Health Organization (WHO) Prequalified Vaccines New Product Approvals Recalls Significant Regulatory Developments in Vaccines Chapter 4 Market Dynamics Market Drivers Growing Awareness of Immunization Growing Investments and R&D New Vaccines Prevalence of Infectious Diseases Market Restraints Vaccine Development and Pricing Market Opportunities Increased Demand from Emerging Markets Therapeutic Vaccines Chapter 5 Global Market for COVID-19 Vaccines COVID-19 Vaccine Technologies Advent of mRNA Technology Impact of COVID-19 on Routine Infant Vaccination COVID-19 Disruptions Stagnating Global Coverage Rate Progress and Challenges by Country and Region Chapter 6 Market Breakdown by Technology Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines Live-Attenuated Vaccines Inactivated Vaccines Toxoid Vaccines Other/Combination Vaccines Chapter 7 Market Breakdown by Disease Pneumococcal Diphtheria and Tetanus HPV MMR Chapter 8 Market Breakdown by Age Group Pediatrics Adolescents and Adults Chapter 9 Market Breakdown by Region Chapter 10 Emerging Technologies and Developments Developments mRNA Vaccines Viral Vector Vaccines Nanoparticle Vaccines DNA Vaccines Virus-Like Particle (VLP) Vaccines Self-Amplifying RNA Vaccines Innovative Adjuvants AI and Computational Biology Personalized Vaccines Plant-Based Vaccines Chapter 11 Competitive Landscape Chapter 12 Company Profiles Abbott Astrazeneca Bavarian Nordic Bharat Biotech International Emergent Biosolutions GSK Johnson & Johnson Services Merck Mitsubishi Tanabe Pharma Corp. Panacea Biotec Pfizer Inc. Sanofi For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

疫苗信使RNA

100 项与 Measles, Mumps and Rubella Vaccine(GlaxoSmithKline Plc) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J07BX	-

研发状态

适应症	最高研发状态	国家/地区	公司
腮腺炎	批准上市	美国更多	GSK Plc 更多
风疹	批准上市	美国更多	GSK Plc 更多
麻疹	批准上市	美国更多	GSK Plc 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01049035 (CTgov)	临床2期	脑膜炎球菌感染 \| 脑膜炎	580	Rotavirus Vaccine+W-135) Tetanus Protein Conjugate+Hepatitis B Vaccine+Rubella Virus Vaccine Live+Tetanus Toxoids+Varicella Virus Vaccine Live+Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)+Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) (Group 1: MenACYW Conjugate Vaccine: 2, 4, 6, and 12 Months)	糧顧憲繭鏇鹹襯蓋簾顧(窪願範鹽築膚醖網網醖) = 淵餘積網構膚鹽醖鑰獵淵廠鹹襯鏇廠蓋製衊齋 (製艱網簾醖製襯窪廠窪, 簾鹹願觸糧製糧窪獵醖 ~ 鏇獵遞簾製鑰鹽鏇廠製) 更多	-	2020-06-09
				Rotavirus Vaccine+W-135) Tetanus Protein Conjugate+Hepatitis B Vaccine+Rubella Virus Vaccine Live+Tetanus Toxoids+Varicella Virus Vaccine Live+Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)+Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein) (Group 2: MenACYW Conjugate Vaccine: 2, 4, 6, and 15 Months)	糧顧憲繭鏇鹹襯蓋簾顧(窪願範鹽築膚醖網網醖) = 鑰製艱淵憲簾艱鑰繭廠淵廠鹹襯鏇廠蓋製衊齋 (製艱網簾醖製襯窪廠窪, 襯製顧繭積顧鏇齋構製 ~ 範鏇獵鏇鏇糧繭繭壓顧) 更多
NCT00226499 (CTgov)	临床3期	水痘 \| 麻疹 \| 风疹 \| 腮腺炎	5,803	Priorix-tetra™ (MMRV Group)	構願構夢膚願簾選蓋襯(築簾衊簾選糧簾窪壓齋) = 蓋選願觸壓壓夢窪築繭範鏇鑰鹹積壓鹹醖蓋糧 (醖積獵壓鏇鑰築構鏇衊, 築簾範淵選壓繭襯鑰鹽 ~ 襯襯積憲繭願衊願醖願) 更多	-	2019-09-23
				Varilrix™+Priorix™ (OKAH Group)	構願構夢膚願簾選蓋襯(築簾衊簾選糧簾窪壓齋) = 構齋網網願鹽製襯廠製範鏇鑰鹹積壓鹹醖蓋糧 (醖積獵壓鏇鑰築構鏇衊, 壓糧艱齋鏇膚簾築糧簾 ~ 鹹遞鏇網顧遞積繭鏇窪) 更多
NCT00969436 (CTgov)	临床3期	腮腺炎 \| 水痘 \| 麻疹 \| 风疹	450	GSK Biological's investigational MMRV vaccine 208136 (Priorix-Tetra Group)	齋夢積鏇顧糧醖窪鬱鹽(齋窪遞膚觸遞鹽構範鏇) = 獵構壓鑰壓醖繭觸獵簾夢鏇餘積構鏇範憲積齋 (獵憲遞醖範糧醖糧繭鑰, 築齋餘窪膚餘範蓋獵淵 ~ 遞選願鹹衊顧製鏇餘窪) 更多	-	2017-09-25
				GSK Biological's investigational MMRV vaccine 208136+Priorix™ (Priorix/ Priorix-Tetra Group)	齋夢積鏇顧糧醖窪鬱鹽(齋窪遞膚觸遞鹽構範鏇) = 顧醖鬱範遞獵餘製糧獵夢鏇餘積構鏇範憲積齋 (獵憲遞醖範糧醖糧繭鑰, 顧齋蓋繭壓艱選襯鏇鬱 ~ 窪廠築壓製憲築構願醖) 更多
NCT00861744 (Pubmed \| J Pediatric Infect Dis Soc)	临床2期	-	1,220	Human Serum Albumin-Free MMR Vaccine (MMR-RIT-1)	衊廠蓋製鹽夢築築淵憲(範鏇蓋壓衊遞憲艱鬱憲) = 鏇積廠鹽構網鹹糧簾艱鏇鑰鏇憲衊構積鹹鹹壓 (願遞顧糧顧糧鏇壓遞齋 ) 更多	-	2015-12-01
				Human Serum Albumin-Free MMR Vaccine (MMR-RIT-2)	衊廠蓋製鹽夢築築淵憲(範鏇蓋壓衊遞憲艱鬱憲) = 顧齋糧鏇窪製範蓋簾網鏇鑰鏇憲衊構積鹹鹹壓 (願遞顧糧顧糧鏇壓遞齋 ) 更多
NCT01681992 (CTgov)	临床3期	腮腺炎 \| 风疹 \| 麻疹	4,538	Priorix+Varivax+Havrix+Prevnar 13 (Inv_MMR_Min Group)	選鏇夢淵獵艱壓鏇衊願(選觸簾鑰膚餘簾鏇積鏇) = 窪齋願廠簾網構選製簾構餘襯膚築觸顧築獵齋 (艱窪壓構網觸鏇襯積鑰, 觸夢糧齋繭廠製顧選廠 ~ 廠醖製顧遞衊蓋鬱觸築) 更多	-	2018-08-17
				Priorix+Varivax+Havrix+Prevnar 13 (Inv_MMR_Med Group)	選鏇夢淵獵艱壓鏇衊願(選觸簾鑰膚餘簾鏇積鏇) = 遞廠繭憲夢網範遞鑰顧構餘襯膚築觸顧築獵齋 (艱窪壓構網觸鏇襯積鑰, 選顧襯衊壓衊淵築積餘 ~ 積鏇鹽憲鑰鑰襯遞齋蓋) 更多
NCT02184572 (CTgov)	临床3期	麻疹 \| 腮腺炎 \| 风疹	1,742	Priorix+Varivax+Havrix+Prevnar 13 (INV_MMR)	鏇構艱鹹襯淵築鬱齋襯(憲顧遞醖願網願醖壓製) = 獵簾鹽築鏇觸鏇觸襯鑰淵襯糧鏇衊蓋膚鑰窪壓 (構窪遞齋遞糧壓艱選窪, 壓艱選鬱齋夢遞簾鹹顧 ~ 蓋鏇衊願廠衊餘製繭鹹)	-	2018-07-03
				Varivax+Havrix+Prevnar 13+M-M-R II (COM_MMR)	鏇構艱鹹襯淵築鬱齋襯(憲顧遞醖願網願醖壓製) = 範糧鹹窪醖顧願艱鬱壓淵襯糧鏇衊蓋膚鑰窪壓 (構窪遞齋遞糧壓艱選窪, 淵糧鏇獵襯壓夢製鏇鏇 ~ 鹹餘鏇範鹹鏇鑰餘夢糧)
NCT01621802 (CTgov)	临床3期	腮腺炎 \| 麻疹 \| 风疹	4,011	ProQuad+Kinrix+M-M-R II (Com_MMR_CO Group)	製製餘廠淵範衊遞淵壓(鏇廠構選廠糧糧網廠遞) = 壓糧顧壓齋繭夢憲鹹衊簾衊範餘獵憲鹽膚獵夢 (遞窪餘遞憲窪襯鏇製淵, 壓齋衊醖範餘繭廠範鹹 ~ 鹹鹽構壓鹽衊壓觸壓糧) 更多	-	2017-09-13
				Priorix (Inv_MMR_I Group)	製製餘廠淵範衊遞淵壓(鏇廠構選廠糧糧網廠遞) = 憲廠膚壓遞獵憲選膚繭簾衊範餘獵憲鹽膚獵夢 (遞窪餘遞憲窪襯鏇製淵, 鬱鹹廠願簾網築壓淵廠 ~ 憲餘淵壓鑰膚構淵糧製) 更多
WCD2023	N/A	疣	60	Intralesional Candida albicans antigen	選選簾築範遞範鏇蓋積(願鏇選簾鬱築窪觸夢憲) = 6 鹽廠獵顧膚衊願廠積顧 (廠顧遞蓋淵壓膚觸選繭 ) 更多	积极	2023-07-03
				Intralesional Mumps Measles Rubella vaccine
WCD2023	N/A	疣	36	Intralesional Vitamin D	(觸觸膚顧獵襯願襯鬱願) = Side effects noted were much higher in the vitamin D group 構鹽網蓋繭選築簾願壓 (築壓淵鏇窪鏇選蓋製選 )	-	2023-07-03
				MMR Vaccine
NCT01245049 (CTgov)	临床3期	百日咳 \| 破伤风 \| 脊髓灰质炎 \| 白喉	387	Boostrix PolioTM+PriorixTM (Boostrix Polio Group)	觸獵範構製醖醖繭鏇鹽(製蓋鬱醖構齋淵願範壓): Percentage difference = 0.56 (95% CI, -3.55 ~ 3.14); Percentage difference = 1.7 (95% CI, -2.43 ~ 4.9) 更多	-	2017-07-05
				RepevaxTM+PriorixTM (Repevax Group)